Cassava Sciences (SAVA) Competitors $26.91 +0.77 (+2.95%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SAVA vs. COLL, NATR, VSTM, CMRX, VRCA, CRNX, BBIO, BHVN, RARE, and IMVTShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Collegium Pharmaceutical (COLL), Nature's Sunshine Products (NATR), Verastem (VSTM), Chimerix (CMRX), Verrica Pharmaceuticals (VRCA), Crinetics Pharmaceuticals (CRNX), BridgeBio Pharma (BBIO), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), and Immunovant (IMVT). These companies are all part of the "medical" sector. Cassava Sciences vs. Collegium Pharmaceutical Nature's Sunshine Products Verastem Chimerix Verrica Pharmaceuticals Crinetics Pharmaceuticals BridgeBio Pharma Biohaven Ultragenyx Pharmaceutical Immunovant Cassava Sciences (NASDAQ:SAVA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment. Which has stronger valuation & earnings, SAVA or COLL? Collegium Pharmaceutical has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$97.22M-$1.38-19.50Collegium Pharmaceutical$566.77M1.68$48.15M$2.3212.75 Does the media refer more to SAVA or COLL? In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 3 mentions for Cassava Sciences. Collegium Pharmaceutical's average media sentiment score of 0.87 beat Cassava Sciences' score of 0.49 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer SAVA or COLL? Cassava Sciences currently has a consensus price target of $111.50, indicating a potential upside of 314.34%. Collegium Pharmaceutical has a consensus price target of $42.60, indicating a potential upside of 44.02%. Given Cassava Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the MarketBeat Community believe in SAVA or COLL? Collegium Pharmaceutical received 287 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 65.77% of users gave Cassava Sciences an outperform vote while only 65.25% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCassava SciencesOutperform Votes9865.77% Underperform Votes5134.23% Collegium PharmaceuticalOutperform Votes38565.25% Underperform Votes20534.75% Is SAVA or COLL more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Cassava Sciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -88.05% -64.98% Collegium Pharmaceutical 14.78%104.67%18.38% Which has more volatility and risk, SAVA or COLL? Cassava Sciences has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Do insiders and institutionals have more ownership in SAVA or COLL? 38.1% of Cassava Sciences shares are owned by institutional investors. 9.0% of Cassava Sciences shares are owned by company insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCollegium Pharmaceutical beats Cassava Sciences on 12 of the 17 factors compared between the two stocks. Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-19.504.8266.7313.27Price / SalesN/A374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book7.789.636.455.92Net Income-$97.22M$154.43M$119.73M$225.73M7 Day Performance-0.15%-9.46%-5.13%-1.34%1 Month Performance-9.01%-7.27%-2.71%1.15%1 Year Performance67.44%28.13%31.08%24.02% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences3.7715 of 5 stars$26.91+2.9%$111.50+314.3%+72.0%$1.29BN/A-19.5030Gap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.1071 of 5 stars$30.25-3.7%N/A+17.8%$975.56M$566.77M13.04210NATRNature's Sunshine Products2.9448 of 5 stars$16.02-2.4%N/A-7.1%$296.05M$445.32M18.20814Positive NewsVSTMVerastem2.9685 of 5 stars$4.01-8.9%N/A-34.0%$178.49M$2.60M-1.2650CMRXChimerix4.4465 of 5 stars$0.96-3.3%N/A-14.0%$86.34M$320,000.00-1.0272Short Interest ↓VRCAVerrica Pharmaceuticals4.6586 of 5 stars$0.87-5.6%N/A-76.0%$39.59M$5.12M-0.4740CRNXCrinetics Pharmaceuticals3.5501 of 5 stars$60.85+3.5%N/A+93.1%$4.87B$4.01M-16.10210Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageBBIOBridgeBio Pharma4.6019 of 5 stars$25.86+5.0%N/A-17.8%$4.86B$9.30M-9.83400Analyst ForecastAnalyst RevisionNews CoverageBHVNBiohaven3.811 of 5 stars$49.76-1.2%N/A+49.6%$4.70B$462.51M-5.44239Earnings ReportAnalyst ForecastNews CoverageRAREUltragenyx Pharmaceutical4.6264 of 5 stars$49.00+2.4%N/A+14.9%$4.52B$434.25M-7.571,276Analyst ForecastIMVTImmunovant1.6351 of 5 stars$28.98-1.0%N/A-21.0%$4.25BN/A-13.05120Positive News Related Companies and Tools Related Companies Collegium Pharmaceutical Competitors Nature's Sunshine Products Competitors Verastem Competitors Chimerix Competitors Verrica Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors BridgeBio Pharma Competitors Biohaven Competitors Ultragenyx Pharmaceutical Competitors Immunovant Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SAVA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAVA Stock Alerts